YaoGeJu

Company directoryChina company filings

Changzhou Sunlight Pharmaceutical Co., Ltd.

As of 18 November 2026, for the company name Changzhou Sunlight Pharmaceutical Co., Ltd. as recorded, the chemical-drug catalogue lists 7 active records with this name as holder; 2 active API registrations list this name as first registered company.

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference

CDE data as of
2026/11/18
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/18.

Drug filings

10 acceptance records as first applicant, grouped into 9 source drug names. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Finerenone Tablets 2 records · Latest accepted 2025/12/18

Generic · 2

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2504310Generic2025/12/18Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗
CYHS2504309Generic2025/12/18Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗
Rosuvastatin Calcium and Ezetimibe Tablets (I) 1 records · Latest accepted 2025/01/07

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2500076Generic2025/01/07Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗
瑞舒伐他汀依折麦布片(II) · No verified English name 1 records · Latest accepted 2025/01/07

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2500077Generic2025/01/07Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗
Felodipine Sustained Release Tablets 1 records · Latest accepted 2024/08/03

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402470Generic2024/08/03Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗
二甲双胍恩格列净片(I) · No verified English name 1 records · Latest accepted 2024/01/16

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2400220Generic2024/01/16Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗
二甲双胍恩格列净片(V) · No verified English name 1 records · Latest accepted 2024/01/16

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2400221Generic2024/01/16Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗
二甲双胍恩格列净片(VI) · No verified English name 1 records · Latest accepted 2024/01/16

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2400222Generic2024/01/16Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗
Telmisartan And Amlodipine Tablets 1 records · Latest accepted 2024/01/09

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2400116Generic2024/01/09Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗
替米沙坦氨氯地平片(II) · No verified English name 1 records · Latest accepted 2024/01/09

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2400117Generic2024/01/09Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗

Changes in the last 90 days

0 events from 2026/08/22 to 2026/11/19. CDE data as of 2026/11/18; NMPA data as of 2026/11/19.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

  1. No matching records were found in the currently loaded source data; coverage dates are listed below.

Under review

2 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Finerenone Tablets CYHS2504310Generic2025/12/18Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗
Finerenone Tablets CYHS2504309Generic2025/12/18Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗

Catalogue holder records

7 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/18. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Rosuvastatin Calcium and Ezetimibe Tablets (I)Changzhou Sunlight Pharmaceutical Co., Ltd.Changzhou Sunlight Pharmaceutical Co., Ltd.国药准字H202649532026/06/23Generic approved under the new chemical-drug registration classificationCDE ↗
Felodipine Sustained Release TabletsChangzhou Sunlight Pharmaceutical Co., Ltd.Changzhou Sunlight Pharmaceutical Co., Ltd.国药准字H202561922025/12/09Generic approved under the new chemical-drug registration classificationCDE ↗
二甲双胍恩格列净片(VI) · No verified English nameChangzhou Sunlight Pharmaceutical Co., Ltd.Changzhou Sunlight Pharmaceutical Co., Ltd.国药准字H202546252025/06/24Generic approved under the new chemical-drug registration classificationCDE ↗
二甲双胍恩格列净片(I) · No verified English nameChangzhou Sunlight Pharmaceutical Co., Ltd.Changzhou Sunlight Pharmaceutical Co., Ltd.国药准字H202546232025/06/24Generic approved under the new chemical-drug registration classificationCDE ↗
二甲双胍恩格列净片(V) · No verified English nameChangzhou Sunlight Pharmaceutical Co., Ltd.Changzhou Sunlight Pharmaceutical Co., Ltd.国药准字H202546242025/06/24Generic approved under the new chemical-drug registration classificationCDE ↗
Telmisartan And Amlodipine TabletsChangzhou Sunlight Pharmaceutical Co., Ltd.Changzhou Sunlight Pharmaceutical Co., Ltd.国药准字H202543512025/05/27Generic approved under the new chemical-drug registration classificationCDE ↗
替米沙坦氨氯地平片(II) · No verified English nameChangzhou Sunlight Pharmaceutical Co., Ltd.Changzhou Sunlight Pharmaceutical Co., Ltd.国药准字H202543522025/05/27Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

2 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/18.

NameCompany / applicantRegistration numberStatusSource update dateView source
非奈利酮 · No verified English nameChangzhou Sunlight Pharmaceutical Co., Ltd.Y20250001089I2025/11/18CDE ↗
苯佐卡因 · No verified English nameChangzhou Sunlight Pharmaceutical Co., Ltd.Y20190006994A2024/04/18CDE ↗

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

3 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/18.

This source was last successfully updated at 2026/11/18; current coverage may be incomplete.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
OLP-210片 · No verified English name CXHB2600152Supplement2026/05/27Shenzhen Ao Li Bio Technology Co., Ltd. romanized; Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗
OLP-210片 · No verified English name CXHB2600151Supplement2026/05/27Shenzhen Ao Li Bio Technology Co., Ltd. romanized; Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗
OLP-210片 · No verified English name CXHB2600150Supplement2026/05/27Shenzhen Ao Li Bio Technology Co., Ltd. romanized; Changzhou Sunlight Pharmaceutical Co., Ltd.CDE ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/18 · Current coverage may be incomplete
Chemical-drug catalogue
Last successful update: 2026/11/18
API registrations
Last successful update: 2026/11/18
NMPA drug delivery notices
Last successful update: 2026/11/19

Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.